Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Usti Nad Labem – page 2

47 clinical trials in Usti Nad Labem, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Usti Nad Labem at a glance
47
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

47 trials in Usti Nad Labem

Open in trial search

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Obesity+1

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Skin ulcer

Not yet recruiting

Safety and Efficacy of EscharEx (concentrate of proteolytic enzymes enriched in bromelain) in Adults with Venous Leg Ulcers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Concentrate of proteolytic enzymes enriched in bromelain
  • Sponsor:Mediwound Ltd.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Contraception

Not recruiting

Study on the Effectiveness and Safety of Levonorgestrel Vaginal Delivery System vs. Desogestrel Tablets for Preventing Pregnancy in Women

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · Healthy volunteers
  • Substances:Desogestrel
  • Sponsor:Chemo Research S.L.

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic skin-derived ABCB5-POSITIVE dermal mesenchymal stromal cells
  • Sponsor:Rheacell GmbH & Co. KG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Hypereosinophilic syndrome

Not recruiting

A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Hidradenitis

Not recruiting

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Hypertriglyceridaemia

Not recruiting

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Usti Nad Labem

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on cardiovascular disease management and prevention, including studies on hypertrophic cardiomyopathy and treatments for acute myocardial infarction.

  • Heart failure treatments
  • Stroke prevention
  • Deep vein thrombosis therapy

Several studies are evaluating novel compounds to reduce cardiovascular events and improve patient outcomes.

02 Gastrointestinal Studies

Multiple clinical investigations targeting Crohn's Disease, with research focusing on innovative therapies and treatment combinations for moderate to severe cases.

  • Inflammatory bowel disease management
  • Novel therapeutic approaches
  • Long-term disease control

Research aims to improve quality of life for patients with chronic gastrointestinal conditions.

03 Metabolic Disorders

Comprehensive research into diabetes management and hypertriglyceridemia, including specialized treatments for both Type 1 and Type 2 diabetes in various age groups.

  • Blood sugar control
  • Lipid management
  • Pediatric diabetes care

Studies focus on developing targeted therapies for better metabolic control.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.